Skip to main content
Clinical Trials/DRKS00006083
DRKS00006083CompletedNot Applicable

Cross-sectional Evaluation of clinical symptoms and epidemiologic parameters in patients with TMA, differentiated by laboratory param-eters (CESAR) - CESAR

Alexion Pharma Germany GmbH0 sites232 target enrollmentStarted: April 23, 2014Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
232

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
one to one (—)
Sex
All

Inclusion Criteria

  • 1. microangiopathic hemolytic anaemia, 2. thrombocytopenia: thrombocytes < 150 x 10´`9/l or thrombocytes decreased by more than 25% during one week, 3. One of the following: neurological symptoms, renal dysfunction, gastrointestinal symptoms

Exclusion Criteria

  • plasma intervention before blood sampling, antibiotic therapy before stool sampling

Investigators

Similar Trials

Cross-sectional Evaluation of clinical... | Clinical Trial